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LRPPRC mutations cause early-onset
multisystem mitochondrial disease outside
of the French-Canadian population
Monika Ola´hova´,1 Steven A. Hardy,1 Julie Hall,2 John W. Yarham,1 Tobias B. Haack,3,4
William C. Wilson,1 Charlotte L. Alston,1 Langping He,1 Erik Aznauryan,1 Ruth M. Brown,5
Garry K. Brown,5 Andrew A. M. Morris,6 Helen Mundy,7 Alex Broomfield,6 Ines A. Barbosa,8
Michael A. Simpson,8 Charu Deshpande,9 Dorothea Moeslinger,10 Johannes Koch,11
Georg M. Stettner,12 Penelope E. Bonnen,13 Holger Prokisch,3,4 Robert N. Lightowlers,1
Robert McFarland,1 Zofia M. A. Chrzanowska-Lightowlers1 and Robert W. Taylor1
Mitochondrial Complex IV [cytochrome c oxidase (COX)] deﬁciency is one of the most common respiratory chain defects in
humans. The clinical phenotypes associated with COX deﬁciency include liver disease, cardiomyopathy and Leigh syndrome, a
neurodegenerative disorder characterized by bilateral high signal lesions in the brainstem and basal ganglia. COX deﬁciency can
result from mutations affecting many different mitochondrial proteins. The French-Canadian variant of COX-deﬁcient Leigh
syndrome is unique to the Saguenay-Lac-Saint-Jean region of Que´bec and is caused by a founder mutation in the LRPPRC
gene. This encodes the leucine-rich pentatricopeptide repeat domain protein (LRPPRC), which is involved in post-transcriptional
regulation of mitochondrial gene expression. Here, we present the clinical and molecular characterization of novel, recessive
LRPPRC gene mutations, identiﬁed using whole exome and candidate gene sequencing. The 10 patients come from seven unrelated
families of UK-Caucasian, UK-Pakistani, UK-Indian, Turkish and Iraqi origin. They resemble the French-Canadian Leigh syn-
drome patients in having intermittent severe lactic acidosis and early-onset neurodevelopmental problems with episodes of deteri-
oration. In addition, many of our patients have had neonatal cardiomyopathy or congenital malformations, most commonly
affecting the heart and the brain. All patients who were tested had isolated COX deﬁciency in skeletal muscle. Functional char-
acterization of patients’ ﬁbroblasts and skeletal muscle homogenates showed decreased levels of mutant LRPPRC protein and
impaired Complex IV enzyme activity, associated with abnormal COX assembly and reduced steady-state levels of numerous
oxidative phosphorylation subunits. We also identiﬁed a Complex I assembly defect in skeletal muscle, indicating different roles for
LRPPRC in post-transcriptional regulation of mitochondrial mRNAs between tissues. Patient ﬁbroblasts showed decreased steady-
state levels of mitochondrial mRNAs, although the length of poly(A) tails of mitochondrial transcripts were unaffected. Our study
identiﬁes LRPPRC as an important disease-causing gene in an early-onset, multisystem and neurological mitochondrial disease,
which should be considered as a cause of COX deﬁciency even in patients originating outside of the French-Canadian population.
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Introduction
The mitochondrial oxidative phosphorylation (OXPHOS)
system is the cell’s primary source of energy produced in
the form of adenosine triphosphate (ATP). This metabolic
pathway comprises the four transmembrane enzyme com-
plexes (CI–IV) of the mitochondrial respiratory chain and
Complex V, the F0F1-ATP synthase. A wide range of paedi-
atric and adult-onset multisystem diseases are associated
with deﬁciencies in the OXPHOS system affecting at least
1 in 4300 individuals (Skladal et al., 2003; Gorman et al.,
2015). Due to the dual genetic (nuclear and mitochondrial
DNA) origin of genes encoding the structural components
of the mitochondrial OXPHOS system, mitochondrial re-
spiratory chain disorders can be inherited as Mendelian
traits, inherited maternally or may occur sporadically.
The clinical presentation of mitochondrial disorders is asso-
ciated with a wide spectrum of organ and tissue involve-
ment and the age of onset can vary. Although the
correlation between the clinical and genetic diversity of re-
spiratory chain disorders is poor and apparent phenotype-
genotype association is often not present, the biochemical
assessment and characterization of the underlying
OXPHOS defect underpins the molecular diagnosis of
these conditions (Spiegel et al., 2014).
Leigh syndrome is an early-onset subacute necrotizing
encephalopathy with typical symmetrical basal ganglia
and/or brainstem involvement. Developmental regression
is a characteristic, but not universal feature. Leigh syn-
drome is commonly associated with isolated cytochrome c
oxidase (COX) deﬁciency due to mutations in several COX
assembly factors, including SURF1, which encodes a bio-
genesis factor participating in the early steps of Complex IV
maturation, the most common cause of COX-deﬁcient
Leigh syndrome (Smith et al., 2005; Bundschuh et al.,
2009; Wedatilake et al., 2013). Mutations in other
nuclear-encoded genes responsible for a generalized de-
crease in COX activity have been identiﬁed; these include
the apoptosis regulator APOPT1 gene (Melchionda et al.,
2014), the Complex IV biogenesis factor PET100 (Lim
et al., 2014; Olahova et al., 2015), SCO1 and SCO2 that
are involved in copper delivery during Complex IV matur-
ation (Leary et al., 2009) and COX10 and COX15, both
of which have a role in the biosynthesis of mitochondrial
heme a (Antonicka et al., 2003; Oquendo et al., 2004;
Bugiani et al., 2005). Other mutations also associated
with COX deﬁciency in humans include TACO1, COA3,
COX14 and LRPPRC, encoding regulators of mitochon-
drial transcription and translation of transcripts encoding
Complex IV subunits (Weraarpachai et al., 2009; Sasarman
et al., 2010, 2015; Szklarczyk et al., 2012; Ostergaard
et al., 2015).
A homozygous c.1061C4T, p.(Ala354Val) founder mu-
tation in the LRPPRC gene underpins the founder French-
Canadian variant of Leigh Syndrome (LSFC) identiﬁed in
the Saguenay-Lac-Saint-Jean region of Que´bec (Mootha
et al., 2003). LRPPRC belongs to a family of pentatrico-
peptide repeat (PPR) proteins containing 35 amino acid
repeat motifs that confer an ability to recognize RNA sub-
strates and thus regulate a number of post-transcriptional
processes such as RNA editing, RNA stability or RNA deg-
radation (Lightowlers and Chrzanowska-Lightowlers,
2008, 2013; Rackham and Filipovska, 2012; Barkan and
Small, 2014). While the precise molecular mechanism of
the seven PPR proteins found in humans remains mostly
unclear, a number of studies have identiﬁed important roles
for PPR proteins in the regulation of RNA metabolism.
Large mitochondrial polycistronic precursor RNAs are pro-
cessed to release the 11 OXPHOS transcripts that are sub-
sequently polyadenylated by the mitochondrial poly(A)
polymerase MTPAP (Tomecki et al., 2004). This process
involves the addition of poly(A) tails (45 nucleotides)
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that is necessary to generate the termination codon at the 3’
end of seven of the mitochondrial transcripts (Ojala et al.,
1981). Recent studies in mice and humans demonstrated
that LRPPRC interacts with the stem-loop RNA-binding
protein SLIRP, and this complex appears to be essential
for the maintenance of polyadenylated mitochondrial tran-
scripts (Bratic et al., 2011; Chujo et al., 2012; Ruzzenente
et al., 2012; Wilson et al., 2014). In addition to its role in
post-transcriptional handling of mitochondrial mRNAs,
LRPPRC has distinct functions in diverse cellular process;
increased expression of LRPPRC has been documented in
various tumours, contributing to the apoptosis resistance of
human cancer cells (Tian et al., 2012) and it has been
identiﬁed as an inhibitor of autophagy and mitophagy via
interaction with the mitophagy initiator Parkin (Zou et al.,
2014).
We performed whole exome and candidate gene sequen-
cing in 10 patients from seven families with mitochondrial
disease presentations characterized by infantile lactic acid-
osis, severely impaired psychomotor development and iso-
lated COX deﬁciency. This approach identiﬁed novel
homozygous and compound heterozygous mutations in
the LRPPRC gene—the ﬁrst cases to be identiﬁed outside
of the Saguenay-Lac-Saint-Jean region of Que´bec. The
levels of LRPPRC protein were decreased in patient sam-
ples and consistent with previous studies, skeletal muscle
and skin ﬁbroblast cell lines of these individuals showed a
marked decrease in the steady-state levels of a number of
mitochondrial mRNAs. In addition, a decrease in steady-
state protein levels of Complex I and Complex IV, accom-
panied by abnormal Complex IV assembly, was detected in
skin ﬁbroblasts, further delineating the role of LRPPRC in
the regulation of mitochondrial post-transcriptional gene
expression.
Materials and methods
Ethics statement
This study was approved and performed under the ethical
guidelines issued by each of our institutions and complied
with the Declaration of Helsinki.
Histochemical and biochemical
analyses
Standard histological and histochemical analyses of diagnostic
skeletal muscle biopsies, including the assay of cytochrome c
oxidase, were performed according to established protocols on
fresh-frozen sections (10 mm) (Old and Johnson, 1989).
Mitochondrial respiratory chain complex activities were deter-
mined in skeletal muscle homogenates and enriched cultured
skin ﬁbroblast mitochondrial fractions as previously described,
and expressed relative to the activity of the matrix marker
enzyme, citrate synthase (Kirby et al., 2007).
Molecular genetic studies
Total DNA was extracted by standard procedures from avail-
able tissues obtained with consent. Copy number abnormal-
ities and rearrangements of mtDNA were excluded by
quantitative PCR and long-range PCR, respectively, whereas
direct sequencing of the entire mitochondrial genome was per-
formed on homogenate skeletal muscle DNA to exclude patho-
genic mtDNA mutations. Direct sequencing of a number of
candidate nuclear genes associated with isolated COX deﬁ-
ciency including SURF1, COX10, COX15, SCO1 and SCO2
were undertaken using standard protocols.
Whole exome sequencing was undertaken to elucidate the
molecular basis of the mitochondrial disease in the probands
from six families (Patients 1, 4, 5, 8, 9 and 10) using previ-
ously described methodologies and bioinformatics ﬁltering
pipelines (Haack et al., 2012; Jones et al., 2012; Bonnen
et al., 2013; Besse et al., 2015). The LRPPRC mutation in
Patient 2 was identiﬁed by candidate gene sequencing of
PCR products ampliﬁed from ﬁbroblast cDNA and conﬁrmed
by genomic DNA sequencing. All mutations were conﬁrmed by
Sanger sequencing of PCR-ampliﬁed products using BigDye
Terminator cycle sequencing chemistry (Applied Biosystems,
ABI) on an ABI3130xl Genetic Analyser. Sequence data was
analysed using Mutation Surveyor software v4.0.9
(SoftGenetics) and compared to the GenBank reference se-
quence, NM_133259.3. Mutation nomenclature is according
to Human Genome Variation Society (HGVS) guidelines.
Cell culture
Primary patient ﬁbroblasts (Patients 1, 2 and 4) and age-
matched control cell lines (Controls 1 and 2) were grown in
Eagle’s Minimal Essential Medium (Sigma) supplemented with
10% (v/v) foetal bovine serum, non-essential amino acids,
1mM sodium pyruvate and 50 mg/ml uridine at 37C in a
humidiﬁed atmosphere of 5% CO2.
Micro-scale oxygraphy analysis
Live cell respiration studies were performed by micro-scale
oxygraphy using the Seahorse XFe Extracellular Flux
Analyzer 24 (Seahorse Bioscience) according to manufacturer’s
instructions and as previously described (Bonnen et al., 2013;
Yarham et al., 2014). Brieﬂy, patient ﬁbroblasts were seeded at
a density of 30 000 cells/well and mitochondrial function was
assayed through the sequential addition of oligomycin
(to 1.3 mM) to block the ATP synthase, two additions of car-
bonyl cyanide 4-(triﬂuoromethoxy)-phenylhydrazone (FCCP),
a respiratory uncoupler that drives maximal respiration
(to 2 mM and then to 3mM), and antimycin A (to 2.5 mM) to
inhibit Complex III.
Oxygen consumption rate (OCR) and proton production
rate measurements for each well were normalized by cell
number. Non-mitochondrial respiration was subtracted from
all OCR values prior to analysis: spare respiratory cap-
acity = maximal OCR basal OCR; ATP coupling efﬁ-
ciency = (basal OCR oligomycin-inhibited OCR)/(basal
OCR  100). Seven separate control cell lines underwent mul-
tiple testing to calculate control data (mean  SD; n = 7),
patient ﬁbroblasts were tested multiple times as indicated in
Fig. 4. An unpaired, two-tailed Student’s t-test was performed
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to determine the signiﬁcance of differences between the data
sets and P-values were considered signiﬁcant at the 95% con-
ﬁdence interval (CI).
Cell lysis and western blot analysis
Control and patient ﬁbroblasts were pelleted and resuspended
in lysis buffer containing 50mM Tris-HCl pH 7.5, 130mM
NaCl, 2mM MgCl2, 1mM phenylmethanesulphonyl ﬂuoride
(PMSF), 1% NonidetTM P-40 (v/v) and EDTA free protease
inhibitor cocktail (Pierce). Cells were lysed on ice for 30min
and lysates were clariﬁed by centrifugation at 500 g for 5min.
Protein concentration was determined by Bradford method
(Bio-Rad). Laemmli sample buffer containing 1% SDS, 10%
glycerol, 10mM Tris-HCl, pH 6.8, 1mM EDTA and 50mM
dithiothreitol was added to the muscle homogenates obtained
as described below. Equal amounts of each protein were
loaded on 12% gels and resolved by sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis (SDS-PAGE), fol-
lowed by wet transfer to polyvinyl diﬂuoride (PVDF)
membrane (ImmobilonTM-P, Millipore Corporation).
Immunodetection was performed using primary and horserad-
ish peroxidise-conjugated secondary antibodies as indicated
(Supplementary material).
Mitochondrial preparation and blue
native electrophoresis
Skin ﬁbroblasts were resuspended in homogenization buffer
(HB) [0.6M mannitol, 1mM EGTA, 10mM Tris-HCl pH
7.4, 1mM PMSF and 0.1 % (v/v) bovine serum albumin
(BSA)] and subjected to 3  15 passes of homogenization
using a Teﬂon glass Dounce homogenizer at 4C.
Mitochondria were separated from nuclei and cell debris by
standard differential centrifugation (400 g for 10min).
Mitochondria were pelleted by centrifugation at 11 000g for
10min at 4C and washed in homogenization buffer without
BSA. Similarly, muscle tissues from Patients 2 and 4 and two
control subjects (30mg) were homogenized using a Teﬂon
glass Dounce homogenizer at 4C (20 strokes) in homogeniza-
tion buffer containing 250mM sucrose, 20mM Imidazole-HCl
pH 7.4 and 1mM PMSF. The muscle homogenates were cen-
trifuged at 20 000g for 10min at 4C and the pellet was
washed twice with 1ml of homogenization buffer at 20 000g
for 5min at 4C. The ﬁnal pellets were solubilized with n-
dodecyl b-D-maltoside (DDM) (Sigma) at 2mg/mg protein
on ice for 20min. Following centrifugation at 100 000g
for 15min at 4C the supernatants were retained for blue
native polyacrylamide gel electrophoresis (BN-PAGE). Protein
concentration was determined with the Pierce BCA
Protein Assay Kit. A minimum of 30 mg of muscle and
100mg of ﬁbroblast protein extracts were loaded on a native
PAGE 4–16 % BisTris gel (Life Technologies) and electrophor-
etically separated in ﬁrst dimension according to the Novex
NativePAGETM Bis-Tris Gel System instructions. Subsequently,
the proteins were immobilized on PVDF membrane and
subjected to standard immunoblotting analysis of OXPHOS
complexes (Supplementary material).
RNA extraction and northern blot
analysis
Total RNA was extracted from ﬁbroblasts and muscle tissues
using TRIzol reagent (Invitrogen) according to manufac-
turer’s instructions. RNA samples (3 mg) were loaded on
1.2% agarose gels, electrophoretically separated under dena-
turing conditions and subsequently transferred to a Genescreen
Plus membrane (Life Science Products, Inc.). 32P-dCTP-labelled
probes were generated from PCR products using random hex-
amer labelled DNA fragments. The radiochemical signal was
visualized by the Typhoon FLA 9500 instrument.
35S metabolic labelling
Mitochondrial translation products in control and patients
ﬁbroblasts were pulse-labelled for 1 h with 200 mCi/ml 35S me-
thionine/cysteine mix (Perkin Elmer) in Dulbecco’s Modiﬁed
Eagle’s medium (Sigma) lacking methionine and cysteine. The
media was supplemented with 100 mg/ml of emetine to inhibit
cytosolic translation [essentially as described in Sasarman and
Shoubridge (2012)]. Protein extracts (15 mg) were electrophor-
etically separated by 15–20% gradient SDS-PAGE and visua-
lized using a Typhoon FLA 9500 instrument.
Results
Case reports
Patient 1 (Family 1)
This girl, the second child of second cousin parents with
two healthy daughters, was born at term by normal deliv-
ery, with a low birth weight of 2320 g. She presented
shortly thereafter with severe lactic acidaemia (20mmol/l)
and coagulopathy. The lactic acidaemia and coagulopathy
resolved with conservative management, but she fed poorly
and by 4 months her weight had fallen below the 0.4th
centile. She was microcephalic and mildly dysmorphic
with a prominent forehead. Psychomotor development
was severely impaired: she was hypotonic and never sat
independently, though at 12 months she could roll from
front to back, transfer an object from hand to hand and
demonstrated polysyllabic babble. Echocardiography was
normal apart from mild mitral regurgitation. From 6
months of age, a chronic hyperlactataemia (4mmol/l) was
punctuated by recurrent episodes of severe lactic acidosis
with ketosis, associated with vomiting and intercurrent ill-
nesses. At 15 months, during one such episode, she de-
veloped pulmonary oedema and was ventilated, but
suffered an asystolic cardiac arrest and died.
Patient 2 (Family 2)
This boy is the third child of ﬁrst cousin parents who have
two healthy daughters. He was born at term by an emer-
gency Caesarean section for foetal distress. Antenatal ultra-
sound had revealed coarctation of the aorta, although this
was not haemodynamically signiﬁcant when assessed
3506 | BRAIN 2015: 138; 3503–3519 M. Ola´hova´ et al.
 by guest on February 25, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
postnatally. By 8 months he was noted to have generalized
hypotonia and was failing to thrive. Beginning at
11 months, he has had repeated hospital admissions with
pneumonia, lactic acidosis (up to 18mmol/l) and ketonuria.
Between episodes, plasma lactate concentrations remained
elevated (2.5–6mmol/l) and the acidosis was managed with
sodium bicarbonate. With the exception of these acute ex-
acerbations his clinical course has been stable. He fed
slowly and, from 5 years, oral feeding has been supple-
mented via a gastrostomy. He has shown very slow devel-
opmental progress and is still unable to sit without support
at 8 years. He can manipulate and transfer objects using a
palmar grasp, reaching non-preferentially with either hand.
Vision and hearing appear normal, but communication is
limited to crying. He is mildly dysmorphic, with a broad
nasal bridge, mild hirsutism and microcephaly (50.4%).
Repeat echocardiography showed bilateral superior vena
cava but no other abnormalities. Plasma amino acid ana-
lysis showed raised alanine concentrations, while urine or-
ganic acids showed increased tricarboxylic acid cycle
intermediates.
Patient 3 (Family 2)
The younger sister of Patient 2, this girl had a birth weight
of 3060 g. She presented at 20 h of age with lactic acidae-
mia (18mmol/l) and hypoglycaemia (1.0mmol/l). There
have been further episodes of acidosis during illnesses,
with a mild chronic lactic acidaemia, similar to her brother.
She has also required treatment with regular sodium bicar-
bonate and tube feeding through a gastrostomy.
Psychomotor development is better than her brother’s. At
2 years, she sat without support and transferred objects
from hand to hand; at 3 years, she crawls and pulls to
stand but she still has no words, communicating by point-
ing and other non-verbal means. As with her brother there
has been no regression. She has a convergent squint, but
vision and hearing are normal. Although not microcephalic
(head circumference on 2nd centile), she has similar fea-
tures to her brother with mild hirsutism and a broad
nasal bridge. Cardiovascular examination and echocardiog-
raphy are normal.
Patient 4 (Family 3)
This boy was born to healthy, non-consanguineous
Caucasian parents following a normal pregnancy; his
mother had a healthy boy by a different partner 11 years
previously. He was born in good condition, but over the
next 2 days became increasingly ﬂoppy and uninterested in
feeds. He suffered several brief generalized seizures and de-
veloped a severe encephalopathy accompanied by central
hypopnoea that required positive airway pressure support
and supplemental oxygen. On examination he demon-
strated profound hypotonia with generalized weakness
and paucity of movement, but intact reﬂexes. There was
no evidence of cardiac, renal or hepatic disease. Capillary
blood gases showed a metabolic acidosis with a consistently
elevated blood lactate. Lumbar puncture revealed an
elevated CSF lactate (5.1mmol/l) and low CSF glucose
(1.3mmol/l) with a decreased CSF:blood glucose ratio
(0.29). The patient continued to deteriorate, developing a
profound persistent metabolic acidosis and severe enceph-
alopathy. He died following withdrawal of care at 6 weeks
of age.
Patient 5 (Family 4)
This girl was the second child to ﬁrst cousin Indian parents
who have had two other affected children (Patients 6
and 7), three miscarriages and a maternal family history
of Zellweger’s syndrome. She was born at term weighing
3250 g after a pregnancy that was complicated by ﬁrst tri-
mester maternal bleeding. Although initially in good condi-
tion, poor oral intake during the ﬁrst 24 h was followed by
hypoglycaemia and she was admitted to the special care
baby unit where elevated blood lactate (16.8mmol/l) and
ammonia (118mmol/l) were noted. Progress with feeding
remained slow and she was discharged at 4 weeks, fed via
nasogastric tube, although by 4 months she had been
weaned onto solid food. Neurodevelopmentally she
showed good progress initially, being able to sit unsup-
ported by 7 months and to stand by 14 months. At
18 months, she developed a protracted gastroenteritic
illness, following which she became increasingly ﬂoppy
and lost some of her previously acquired developmental
skills. Assessment at 2 years 3 months revealed that she
was able to stand with support, walk holding hands, had
an immature pincer grip and was able to transfer objects
from hand to hand. She had no clear words but did babble
and, on testing, had normal hearing. Examination revealed
mild hypotonia with normal reﬂexes and no obvious facial
asymmetry or overt dysmorphism.
Patient 6 (Family 4)
The older sister of Patient 5, this girl was born after induc-
tion of labour at 39 weeks weighing 2660 g. First trimester
ultrasound scanning had shown increased nuchal thickness
and although subsequent chorionic villus sampling con-
ﬁrmed a normal female karyotype, a detailed antenatal car-
diac scan revealed a complex cardiac malformation with
hypoplastic left heart, atrio-ventricular septal defect and
aortic and mitral valve atresiae. At birth she was in good
condition, but was noted to have increased nuchal folds,
micrognathia, low set ears and an anteriorly placed anus.
Blood lactate was elevated and skin and skeletal muscle
biopsies were performed opportunistically during the ﬁrst
stage of cardiac surgery to correct the cardiac malforma-
tions. Although initial recovery from the procedure was
uneventful, on postoperative Day 3 (Day 8 of life), blood
lactate was markedly elevated (15mmol/l), discordant with
haemodynamic status. The following day the baby died
suddenly after an unexplained cardiopulmonary collapse.
Patient 7 (Family 4)
This is the younger sister of Patient 5 who was born by
spontaneous vaginal delivery at term, following an
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uneventful pregnancy, weighing 3600 g. She was in good
condition at birth and did not require resuscitation.
However, she subsequently developed intermittent tachyp-
noea and was transferred to the special care baby unit
where she was noted to have low blood glucose and ele-
vated blood lactate. She had a poorly co-ordinated swallow
and has been fed via nasogastric tube since this time.
Germinal cysts were noted on cranial ultrasound, which
was otherwise normal. Blood lactate subsequently stabilized
but remained mildly raised (2–3mmol/l) at the time of her
discharge home. At 9 weeks she was able to smile and she
could grasp objects in her hand. Head control was con-
sidered age appropriate. She has gastro-oesophageal reﬂux
in addition to her dysphagia but clinical examination was
normal with a head circumference of 38.2 cm (25th centile).
Patient 8 (Family 5)
This boy was the ﬁrst child of ﬁrst cousin Turkish parents
born at term by vaginal delivery following a normal preg-
nancy and weighing 2080 g with a head circumference of
30 cm. He did not require immediate resuscitation but over
the ﬁrst few hours of life developed a tachypnoea and lactic
acidosis (9.4mmol/l) requiring transfer to intensive care.
On examination he was noted to be hypotonic and had
hypospadias and an inguinal hernia. Echocardiograph re-
vealed a mild hypertrophic cardiomyopathy. Clotting was
deranged with a prolonged APTT of 120 s and Factor VIII
activity was recorded at 51%, consistent with a diagnosis
of Haemophilia A. Therapy with sodium bicarbonate and
recombinant Factor VIII was commenced and he was
discharged to outpatient follow-up. Neurodevelopmental
progress was very slow and head growth remained poor.
He developed a progressive spastic dystonic movement dis-
order with nystagmus. Weight gain was poor and he suf-
fered a number of (aspiration) pneumonias. At age 4 years
he was admitted to hospital in acute respiratory failure and
during this admission a PEG (percutaneous endoscopic
gastrostomy) was inserted. He died a few months later
following another admission in acute respiratory failure
complicated by bleeding.
Patient 9 (Family 6)
This boy was the ﬁrst child of ﬁrst cousin UK-Pakistani
parents and was born at 36 weeks gestation, weighing
1780 g, following a labour complicated by foetal distress.
He was dysmorphic with features of micrognathia, poly-
syndactyly and hypospadias. Renal impairment was noted
on Day 2 and raised creatinine persisted throughout life.
Ultrasound examination revealed small, hyperechoic kid-
neys with poor corticomedullary differentiation and a tra-
beculated bladder. Echocardiography showed a bicuspid
aortic valve. Feeding was poor, necessitating supplemental
feeding with a nasogastric tube. A persistent lactic acidosis
of 4–5mmol/l was noted and CSF lactate was 3.41mmol/l.
Muscle biopsy showed only mild ﬁbre size variation, but
with deﬁciency of Complex IV. He became increasingly
unwell with repeated episodes of pneumonia and died at
age 6 months.
Patient 10 (Family 7)
This girl is the second of two children of ﬁrst cousin Iraqi
parents and was born at term by emergency Caesarean sec-
tion for foetal distress weighing 4150 g. No obvious facial
dysmorphism was observed. At 6 months, developmental
delay, muscular hypotonia, truncal ataxia and dysmetria
were noticed. During viral infections the ataxia worsened
and she lost motor skills. At best, the girl was able to
walk with support. Serum lactate ranged between normal
and 7.8mmol/l and CSF lactate was 4.0mmol/l. At age 23
months, following an acute upper respiratory tract infection,
the girl developed constant esotropia of the right eye, signiﬁ-
cant motor regression, dysphagia, arterial hypertension and
left ventricular hypertrophy. Dysphagia required PEG inser-
tion. At age 24 months RSV bronchiolitis led to respiratory
insufﬁciency and intermittent mechanical ventilation, fol-
lowed by tracheostomy and long-term ventilation. At age
27 months, the girl is receiving palliative care at home.
Neuroimaging results
Six of the 10 patients presented in this case series [Patients 1,
2, 4, 8 (on three occasions), 9 and 10] had cranial MRI
scans, showing a range of abnormalities; four of six patients
(Patients 1, 2, 4 and 9) demonstrated a spectrum of congeni-
tal abnormalities listed in detail in Table 1. There are known
associations between mitochondrial disorders (e.g. pyruvate
dehydrogenase deﬁciency) and dysgenesis of the corpus cal-
losum, but this has not been previously described in associ-
ation with LRPPRC mutation. Two of six patients (Patients
8 and 10) demonstrated symmetrical signal changes invol-
ving the brainstem on cranial MRI typical of the neurora-
diological features of Leigh syndrome (Fig. 1A–C). A further
two patients (Patients 1 and 2) showed symmetrical signal
changes in the basal ganglia and cerebellum, but without
evidence of brainstem involvement and their clinical course
was not typical for Leigh syndrome. Three of the patients
(Patients 2, 8 and 10) also demonstrated striking symmet-
rical leukoencephalopathy with avid restricted diffusion, a
feature not previously documented in cases with LRPPRC
mutation (Fig. 1D–F). In Patient 8, the rapidly progressive
nature of this cystic leukoencephalopathy was further cata-
logued on imaging at 7, 8 and 11 months of age as shown in
later scans in Fig. 1F and I. In addition, the single voxel
proton magnetic resonance spectrum acquired on Patient 8
demonstrated elevated lactate (data not shown).
Skeletal muscle and fibroblast
respiratory chain enzyme activities
Investigation of diagnostic muscle biopsies available from
seven patients revealed severe and isolated histochemical
COX defects (Patients 1, 2, 4, 5, 6, 8 and 9) and isolated
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Complex IV deﬁciency in muscle (Table 2), with normal
activities of other respiratory chain complexes.
Interestingly, we noted normal mitochondrial respiratory
chain activities, including Complex IV, in ﬁbroblasts from
some patients (Patients 1 and 2) although a defect was
observed in the cells from Patient 5, later conﬁrmed to
harbour the same genetic variant as Patients 1 and 2, and
to a lesser extent in Patients 4 and 10 (Table 2).
Whole exome sequencing identifies
biallelic LRPPRC mutations
Mutations in the mitochondrial genome (mtDNA re-
arrangements and mtDNA point mutations) were excluded,
as were mutations in a number of candidate nuclear genes
involved in COX assembly including SURF1, SCO1,
SCO2, COX10 and COX15 by Sanger sequencing.
DNA from six probands (Patients 1, 4, 5, 8, 9 and 10)
was subjected to whole exome sequencing, ﬁltering the raw
data in a step-wise process to prioritize genes encoding pro-
teins with a known or predicted mitochondrial localization
harbouring rare, recessively-inherited (compound heterozy-
gous or homozygous) variants (Mayr et al., 2012; Bonnen
et al., 2013). This allowed us to identify causal mutations in
the LRPPRC gene in all six patients, including the same
homozygous c.3900+1G4T mutation in Patients 1, 5 and
9, which abolishes the consensus donor splice site of intron
35 leading to complete skipping of exon 35 as conﬁrmed by
cDNA studies (Supplementary Fig. 1A–C and Supplementary
material); the homozygous c.3900+1G4T mutation was
also identiﬁed in Patient 2 by candidate gene screening.
Patient 4 harboured compound heterozygous mutations
including a c.3147dupA frameshift mutation and a
c.1582+7A4G mutation predicted, and subsequently con-
ﬁrmed, to lead to aberrant splicing (Supplementary Fig. 1D).
Patient 8, the son of consanguineous ﬁrst cousin Turkish
parents harboured a novel c.2595_2597delGGT mutation,
and Patient 10 harboured a novel c.2726_2728delAGA mu-
tation. Where available, testing of parental samples con-
ﬁrmed carrier status and the analysis of DNA samples
from affected siblings showed segregation of the mutant al-
leles with a clinical phenotype (Fig. 2).
Loss of LRPPRC is associated with
decreased respiration
We investigated the biochemical phenotype of mutant
LRPPRC derived from skin ﬁbroblasts and muscle hom-
ogenates of two affected individuals with the homozygous
c.3900 + 1G4T, p.(Gly1050Argfs*4) LRPPRC mutation
(Patients 1 and 2) and a patient with c.[1582 + 7A4G];
c.[3147dupA], p.[=,Glu497*];[Gly1050Argfs*4] compound
heterozygous mutations (Patient 4). First, we determined
the steady-state levels of LRPPRC in patients’ ﬁbroblasts
and muscle protein extracts by western blot analysis, con-
ﬁrming a marked decrease in the steady-state levels of
LRPPRC protein in ﬁbroblasts from all patients compared
to age-matched controls (Fig. 3A). Mitochondrial protein
Table 1 Neuroimaging features identified in patients with LRPPRC mutations
Patient ID Age at scan Congenital abnormalities Acquired abnormalities
Patient 1 1 year old Partial agenesis of corpus callosum
Hippocampal malformation
Abnormal signal observed in dentate nuclei and fastigial
nuclei of the cerebellum and posterior putamina
Patient 2 4 years old Mega cisterna magna
Hypoplastic cerebellar vermis
Hypoplastic cerebellar tonsils
Unfolded hippocampi
Supratentorial central and cerebellar atrophy
Symmetrical abnormal T2 signal in corpus callosum, corpus striatum
and supratentorial subcortical white matter (U fibres) –
also restricts on DWI
Symmetrical abnormal signal of dentate nuclei but no DWI changes
Thalami spared
Patient 4 1 month old Unfolded hippocampi None reported
Patient 8 Scanned at 7, 8 and
11 months of age
None reported Progressive central atrophy and ventricular dilatation
Prominent cystic periventricular white matter changes
including corpus callosum (sparing of U fibres) - avid
restricted diffusion on DWI
Symmetrical cerebellar white matter, putaminal and
dentate nuclei and midbrain and medulla signal changes
Patient 9 3 months old Simplified gyral pattern
Under operculization of the sylvian fissures
Bilateral frontal polymicrogyria
Bilateral parieto-occipital pachygyria
Low lying torcula
None reported
Patient 10 14 months old None reported Symmetrical signal changes involving the corpus callosum,
spinocerebellar and inferior olivary tracts
All associated with restricted diffusion
DWI = diffusion-weighted imaging.
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extracts from muscle of Patients 2 and 4 also showed a
marked decrease in the steady-state levels of the mutant
LRPPRC protein (Fig. 3B).
To further characterize the biochemical phenotype in
LRPPRC patients, OCR were measured in patients’ ﬁbro-
blasts. A signiﬁcant decrease in basal OCR was observed in
Patients 2 and 4 ﬁbroblasts when compared to the control
cell line (Fig. 4A). In addition, basal ECAR (extra-cellular
acidiﬁcation rate), a measure of glycolysis, was signiﬁcantly
increased in ﬁbroblasts from Patient 4 in comparison with
the controls, suggesting that patient ﬁbroblasts are compen-
sating for reduced ATP synthesis resulting from decreased
mitochondrial respiration through increased glycolysis
(Fig. 4B). Interestingly, however, basal ECAR in ﬁbroblasts
from Patient 2 was raised but not signiﬁcantly different to
controls (Fig. 4B). The spare respiratory capacity of Patient
2 ﬁbroblasts was signiﬁcantly reduced in comparison to
control, suggesting that the mitochondria are working at
Figure 1 Brain abnormalities in patients harbouring LRPPRC mutations identified by cranial magnetic resonance imaging.
(A) Axial T2 demonstrating symmetrical T2 hyperintensity in the putamina (Patient 8). (B) Axial T2 demonstrating symmetrical medullary and
cerebellar hyperintensity (Patient 8). (C) Coronal T2 demonstrating symmetrical putaminal and periventricular T2 hyperintensity (Patient 10).
Appearances in A–C are consistent with Leigh syndrome phenotype. (D–F) Axial T2 images of the brain with corresponding diffusion-weighted
imaging sequences (G–I) demonstrating active demyelinating leucoencephalopathy involving the subcortical U-fibres, basal ganglia and corpus
callosum in D, E, G and H (Patient 2) and cystic demyelination in the deep white matter in F and I (Patient 8).
3510 | BRAIN 2015: 138; 3503–3519 M. Ola´hova´ et al.
 by guest on February 25, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
T
a
b
le
2
C
li
n
ic
a
l,
m
o
le
c
u
la
r
a
n
d
b
io
c
h
e
m
ic
a
l
c
h
a
ra
c
te
ri
st
ic
s
o
f
p
a
ti
e
n
ts
w
it
h
L
R
P
P
R
C
m
u
ta
ti
o
n
s
P
a
ti
e
n
t
ID
(S
e
x
)
F
a
m
il
y
F
a
m
il
y
h
is
to
r
y
C
o
u
n
tr
y
o
f
o
ri
g
in
A
g
e
o
f
o
n
se
t/
a
g
e
a
t
la
st
fo
ll
o
w
-u
p
C
li
n
ic
a
l
p
re
se
n
ta
ti
o
n
s
%
R
e
si
d
u
a
l
C
o
m
p
le
x
IV
A
c
ti
v
it
y
c
L
R
P
P
R
C
m
u
ta
ti
o
n
s
M
u
sc
le
H
e
a
rt
C
N
S
C
ra
n
ia
l
M
R
I
D
e
v
e
lo
p
m
e
n
ta
l
d
e
la
y
L
a
c
ti
c
a
c
id
o
si
s
D
y
sp
h
a
g
ia
H
y
p
o
g
ly
c
a
e
m
ia
P
1
(F
)
Fa
m
ily
1
2
n
d
co
u
si
n
s
U
K
-P
ak
is
ta
n
i
B
ir
th
/1
5
m
o
n
th
sa
+
+
+
+
+
+
b
+
–
2
9
(M
);
7
0
(F
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
in
m
u
sc
le
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
2
(M
)
Fa
m
ily
2
1
st
co
u
si
n
s
U
K
-P
ak
is
ta
n
i
8
m
o
n
th
s/
8
ye
ar
s
+
–
+
+
+
+
+
–
3
(M
);
7
0
(F
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
in
m
u
sc
le
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
3
(F
)
Fa
m
ily
2
1
st
co
u
si
n
s
U
K
-P
ak
is
ta
n
i
B
ir
th
/3
ye
ar
s
–
–
+
n
.d
.
+
+
b
+
+
n
.d
.
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
4
(M
)
Fa
m
ily
3
u
n
re
la
te
d
U
K
-C
au
ca
si
an
2
d
ay
s/
6
w
e
e
k
sa
+
–
+
+
–
+
b
+
+
2
1
(M
);
3
0
(F
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
in
m
u
sc
le
c.
[1
5
8
2
+
7
A
4
G
];
[3
1
4
7
d
u
p
A
]:
p
.[
=
,
G
lu
4
9
7
*]
;[
G
ly
1
0
5
0
A
rg
fs
*4
]
P
5
(F
)
Fa
m
ily
4
1
st
co
u
si
n
s
U
K
-I
n
d
ia
n
1
d
ay
/3
ye
ar
sa
+
–
+
n
.d
.
+
+
b
+
+
3
3
(M
);
1
4
(F
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
6
(F
)
Fa
m
ily
4
1
st
co
u
si
n
s
U
K
-I
n
d
ia
n
B
ir
th
/9
d
ay
sa
–
+
–
n
.d
.
–
+
b
–
n
.d
.
4
1
(M
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
7
(F
)
Fa
m
ily
4
1
st
co
u
si
n
s
U
K
-I
n
d
ia
n
B
ir
th
/9
w
e
e
k
s
–
–
–
n
.d
.
–
+
b
+
+
n
.d
.
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
8
(M
)
Fa
m
ily
5
1
st
co
u
si
n
s
Tu
rk
is
h
B
ir
th
/4
ye
ar
sa
+
+
+
+
+
+
b
+
–
2
2
(M
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
H
o
m
o
zy
go
u
s
c.
2
5
9
5
_
2
5
9
7
d
e
lG
G
T
:
p
.(
V
al
8
6
6
d
e
l)
P
9
(M
)
Fa
m
ily
6
1
st
co
u
si
n
s
U
K
-P
ak
is
ta
n
i
B
ir
th
/6
m
o
n
th
sa
–
+
+
+
–
+
+
–
3
3
(M
);
u
n
ifo
rm
C
O
X
h
is
to
ch
e
m
ic
al
d
e
fe
ct
in
m
u
sc
le
H
o
m
o
zy
go
u
s
c.
3
9
0
0
+
1
G
4
T
:
p
.A
rg
1
2
7
6
_
Ly
s1
3
0
0
d
e
l
P
1
0
(F
)
Fa
m
ily
7
1
st
co
u
si
n
s
Ir
aq
i
6
m
o
n
th
s/
2
7
m
o
n
th
s
+
+
+
+
+
+
+
–
3
7
(F
)
H
o
m
o
zy
go
u
s
c.
2
7
2
6
_
2
7
2
8
d
e
lA
G
A
:
p
.(
Ly
s9
0
9
d
e
l)
a
ag
e
at
d
e
at
h
;
b
la
ct
ic
ac
id
ae
m
ia
at
b
ir
th
;
c
m
it
o
ch
o
n
d
ri
al
C
o
m
p
le
x
IV
ac
ti
vi
ty
is
e
x
p
re
ss
e
d
as
a
p
e
rc
e
n
ta
ge
o
f
co
n
tr
o
l
m
e
an
va
lu
e
s
fo
r
e
n
zy
m
e
ac
ti
vi
ty
re
la
ti
ve
to
ci
tr
at
e
sy
n
th
as
e
ac
ti
vi
ty
as
d
e
te
rm
in
e
d
in
sk
e
le
ta
l
m
u
sc
le
(M
)
an
d
fi
b
ro
b
la
st
s
(F
);
n
.d
.=
n
o
t
d
e
te
rm
in
e
d
.
LRPPRC mutations in mitochondrial disease BRAIN 2015: 138; 3503–3519 | 3511
 by guest on February 25, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
near-maximal capacity, with little capability to respond to
increased energy demand. However, Patient 4 ﬁbroblasts
showed an unchanged spare respiratory capacity
(Fig. 4C). The efﬁciency of the coupling of respiration
and ATP synthesis (oligomycin-sensitive OCR as a per
cent of basal OCR) was unchanged in patient ﬁbroblasts
compared to controls, indicating normal levels of proton
leak across the membrane (Fig. 4D). Importantly, patient
cells containing reduced levels of LRPPRC protein display a
biochemical phenotype, the nature of which was further
investigated.
Steady-state levels of respiratory
chain components and complexes
The steady-state protein levels of subunits of mitochondrial
respiratory chain complexes in LRPPRC patient samples
were analysed by SDS-PAGE and immunoblotting.
Homozygous mutant LRPPRC (Patients 1 and 2) and
compound heterozygous mutant LRPPRC (Patient 4)
ﬁbroblasts showed an almost complete loss of mitochon-
drial (COXI and COXII) and nuclear-encoded (COXIV)
subunits of Complex IV (Fig. 5A). The steady-state levels
of Complex I subunit proteins NDUFB8, NDUFA9 and
NDUFA13 were also decreased in Patients 2 and 4 ﬁbro-
blasts. The levels of mitochondrial encoded Complex III
subunit UQCRC2 were markedly decreased in Patient 4
ﬁbroblasts compared to control cell lines, but normal or
increased in the homozygous LRPPRC patient ﬁbroblasts
(Patients 1 and 2) (Fig. 5A). Interestingly, protein loss in
each case was more severe in Patient 4, perhaps reﬂecting
the more severe compound heterozygous frameshift and
splice-site mutations. The nuclear-encoded subunits of
Complex II and Complex V did not show any loss of pro-
tein (Fig. 5A).
Consistent with the reduced steady-state levels of
Complex IV subunits in LRPPRC patient ﬁbroblasts, mito-
chondrial protein extracts from muscle homogenates also
revealed a signiﬁcant decrease in the steady-state levels of
COXI and COXII (Fig. 5B). In addition, slightly decreased
levels of Complex I subunit proteins NDUFB8 and
Figure 2 Family pedigrees and LRPPRC mutations and gene structure. (A) Pedigrees of the seven families with mutations in the LRPPRC
gene. (B) A graphical representation of the LRPPRC gene structure illustrating mutated residues identified within the seven affected families. The
coding regions are shown in blue and the predicted mitochondrial targeting sequence of the protein in green. The RNA binding domain is
represented in red, while the 20 PPR domains are shown in beige.
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NDUFA9 were found in LRPPRC patients’ muscle hom-
ogenates, whilst the levels of Complex V and Complex III
subunits remained unchanged (Fig. 5B).
The assembly of OXPHOS complex subunits into mito-
chondrial respiratory chain complexes was subsequently
analysed by blue native PAGE in LRPPRC patient ﬁbro-
blasts and skeletal muscle. Blue native PAGE analysis
showed a slight decrease of fully assembled Complex IV
in Patient 1 and 2 ﬁbroblasts carrying the homozygous
c.3900 + 1C4T mutation and an almost complete lack of
Complex IV in the muscle of Patient 2 (Fig. 5C).
Additionally, LRPPRC patient muscle homogenates
Figure 4 Dysfunction of mitochondrial respiration in LRPPRC patient fibroblasts. (A) Micro-scale oxygraphy analysis of live fibro-
blasts (XF24 Analyzer, Seahorse Biosciences) demonstrated a respiratory deficiency in cells from both the patient carrying the homozygous
mutation (Patient 2, P2) (n = 17, open triangles) and the patient carrying the compound heterozygous mutation (Patient 4, P4) (n = 16, open
circles) compared to control fibroblasts (n = 160, filled squares). Both basal (prior to oligomycin injection) and maximal (post-FCCP injection)
OCR were significantly reduced (P5 0.05). (B) Basal ECAR (extra-cellular acidification rate), a measure of glycolysis in fibroblasts from Patient 4
was significantly increased in comparison to controls. The basal ECAR in fibroblast derived from Patient 2 was raised but not significantly different
to controls. (C) The spare respiratory capacity (maximal OCR minus basal OCR) of Patient 2 fibroblasts was significantly decreased in com-
parison to controls; however, the spare respiratory capacity in Patient 4 fibroblasts was unchanged. (D) The coupling efficiency of respiration
(oligomycin-sensitive OCR as per cent of basal OCR) was not changed in Patient 2 and Patient 4 fibroblasts compared to controls.
Figure 3 Steady-state LRPPRC protein levels are reduced
in LRPPRC patient tissues. Western blot analysis of LRPPRC
levels in protein extracts isolated from (A) fibroblasts and (B)
skeletal muscle of control (C1, C2), homozygous LRPPRC (Patients 1
and 2; P1, P2) and compound heterozygous (Patient 4, P4) LRPPRC
patients. In (A) b-actin and in (B) UQCRC2 antibodies were used as
loading controls.
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displayed decreased levels of Complex I, similar to previ-
ously published studies (Fig. 5C) (Sasarman et al., 2015).
The amounts of fully assembled Complexes I, III, IV and V
were markedly decreased in Patient 4 ﬁbroblasts, likely due
to the more severe nature of the compound heterozygous
LRPPRC gene mutations. Interestingly however, this was
not the case in Patient 4’s muscle homogenates, where the
assembly proﬁle of Complex III and Complex V was
normal.
The absence of LRPPRC affects the
stability of mitochondrial transcripts
Loss of LRPPRC has been previously associated with a
decrease in the steady-state levels of mitochondrial
mRNA transcripts (Sasarman et al., 2010, 2015; Bratic
et al., 2011; Ruzzenente et al., 2012). We investigated the
effect of LRPPRC mutations on the stability of mitochon-
drial mRNAs in ﬁbroblasts and skeletal muscle samples
from control and LRPPRC patients. In both tissues we de-
tected decreased steady-state levels of MTCO1, MTCO2,
MTND1 and RNA14 transcripts (Fig. 6A). These data are
in agreement with previously published work showing
decreased mitochondrial transcript levels in tissues derived
from LSFC patients (Sasarman et al., 2010, 2015) and
LRPPRC knockdown cell lines (Cooper et al., 2008).
Studies in humans and mice have shown that LRPPRC
forms a ribonucleoprotein complex with SLIRP and this
complex protects the non-translated mitochondrial mRNA
transcripts (Sasarman et al., 2010; Chujo et al., 2012;
Ruzzenente et al., 2012). Loss of SLIRP mimics the post-
transcriptional defect observed in LSFC patient ﬁbroblasts,
thus highlighting their functional dependence. As expected
the steady-state protein levels of SLIRP decreased and re-
ﬂected the levels of LRPPRC in patient ﬁbroblasts (Fig. 6B).
In addition to its role in the regulation of mRNA stabil-
ity, LRPPRC has been also implicated in the regulation of
mitochondrial mRNA polyadenylation (Bratic et al., 2011;
Chujo et al., 2012; Ruzzenente et al., 2012; Wilson et al.,
2014). Therefore, we assessed any changes in the length of
the poly(A) tail in the mitochondrial RNA14 transcript in
the homozygous (Patient 2) and compound heterozygous
(Patient 4) LRPPRC ﬁbroblasts using a poly(A) tail length
assay (Temperley et al., 2010). Analysis of the mitochon-
drial RNA14 transcript showed that polyadenylation in
both Patients 2 and 4 ﬁbroblasts was similar to the control
cell line (Supplementary Fig. 2). In addition, we found that
the steady-state levels of the poly(A) polymerase interacting
Figure 5 Steady-state levels of OXPHOS components and complexes. Western blot analysis of subunits of the respiratory chain
complexes in (A) cell lysates of fibroblasts and (B) mitochondrial extracts of muscle isolated from control (C1, C2), homozygous LRPPRC (Patient
1, P1; Patient 2, P2) and compound heterozygous LRPPRC (Patient 4, P4) patient samples. Subunit-specific antibodies were used against CI
(NDUFA13, NDUFA9, NDUFB8), CII (SDHA), CIII (UQCRC2), CIV (COXI, COXII, COXIV) and CV (ATP5A, ATPB). (A and B) LRPPRC patient
fibroblasts and muscle show an almost complete loss of respiratory chain subunits from Complex IV, as well as significant loss of some subunits
from Complex I. Complex III showed a mild loss of subunit UQCRC2 in Patient 4 fibroblasts, while Complex V showed no loss of protein in
either patient fibroblasts or muscle samples. The nucleus-encoded Complex II (SDHA), cytosolic b-actin and the outer mitochondrial membrane
marker TOM20 were used as loading controls. (C) Mitochondrial proteins from fibroblasts and skeletal muscle samples of control (C1, C2) and
homozygous LRPPRC (Patients 1 and 2) and compound heterozygous LRPPRC (Patient 4) patients were extracted in DDM and analysed by one-
dimensional Blue Native PAGE. Subunit-specific antibodies [CI (NDUFA9), CII (SDHA), CIII (UQCRC2), CIV (COX1) and CV (ATP5A)] were
used to assess the assembly of individual OXPHOS complexes. Immunoblot analysis revealed decreased amounts of fully assembled Complex IV in
patient fibroblasts and muscle compared to age-matched controls. A decrease in Complex I assembly was observed in LRPPRC patients muscle
(Patients 2 and 4) and compound heterozygous fibroblasts (Patient 4). Complex II (SDHA) was used as a loading control.
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protein ATAD3 (encoded by ATAD3A) were also normal
in LRPPRC patient skin cell lines (Fig. 6B) (He et al.,
2012).
To determine whether the observed reduction in steady-
state levels of mitochondrial mRNAs caused by mutated
LRPPRC, affected the translation of mitochondrially-
encoded proteins, 35S-methionine/cysteine pulse labelling
was performed. Patients 1 and 2, harbouring the homozy-
gous c.3900 + 1G4T mutation, showed a mild decrease in
the synthesis of COX1, whereas the translation of other
mtDNA-encoded polypeptides was the same or slightly
increased compared to control ﬁbroblasts (Fig. 6C). A
severe decrease in the de novo protein synthesis of almost
all mitochondrial-encoded polypeptides was observed in
Patient 4 (Fig. 6C).
Discussion
The occurrence of LSFC is common to the Saguenay-Lac-
Saint-Jean region of Que´bec, with a carrier frequency esti-
mated at 1/23 inhabitants in Saguenay-Lac-Saint-Jean, with
1 in 2000 individuals being affected (Morin et al., 1993).
LSFC is caused by a founder mutation in the LRPPRC
gene: in a study of 56 patients, 55 were homozygous for
the c.1061C4T, p.(Ala354Val) mutation, while one indi-
vidual was compound heterozygous for this mutation in
trans with a c.3830_3837del, p.(Cys1277*) mutation
(Debray et al., 2011). Using a whole-exome sequencing ap-
proach, we have identiﬁed novel pathogenic LRPPRC mu-
tations in 10 patients from outside the French-Canadian
population. None of these carried the p.(Ala354Val) foun-
der mutation. Instead, we found three novel homozygous
mutations in LRPPRC: c.3900 + 1G4T, p.(Arg1276_
Lys1300del); c.2595_2597delGGT, p.(Val866del) and
c.2726_2728delAGA, p.(Lys909del); and a genetic
compound c.[1582 + 7A4G];[3147dupA], p.[=,Glu497*];
[Gly1050Argfs*4]. Of these, p.(Arg1276_Lys1300del)
may be relatively common in the Indian subcontinent: it
was found in all four families who originated from there,
although they were unrelated and came from different
regions.
Our patients’ clinical features resembled LSFC in many
respects. As a group, however, our patients were more se-
verely affected; presumably this reﬂects the severity of their
mutations compared with the founder mutation in LSFC.
Figure 6 The effect of LRPPRC mutations on the steady-state levels of mitochondrial mRNAs and mitochondrial translation
products. (A) Mitochondrial mRNAs in fibroblasts and skeletal muscle from LRPPRC patients were significantly reduced. Total RNA was isolated
from control and patient fibroblasts and muscle, and the levels of mitochondrial mRNAs were analysed by northern blotting. Probes against
specific mitochondrial open reading frames, COXI, COXII, ND1 and RNA14 were used and a probe for the 5S cytosolic rRNA was used as loading
control. (B) Reduction in SLIRP steady-state protein levels in the LRPPRC patient fibroblasts were confirmed by western blot analysis. b-Actin
was used as loading control. (C) Analysis of mitochondrial-encoded polypeptides by 35S methionine/cysteine pulse labelling revealed a marked
decrease in mitochondrial translation in the compound heterozygous patient cells (Patient 4) compared to age-matched controls (C1 and C2).
Coomassie Brilliant Blue (CBB) staining was used to check for equal loading of the samples.
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Thus, all our patients had severe neurodevelopmental im-
pairment; the least affected (Patient 5) having no language
acquisitions. Most of our patients have had episodes of
neurological deterioration, as described in LSFC; Patients
2 and 3 have been stable for a number of years, resembling
older LSFC patients. Neurological problems in our patients
have included motor difﬁculties (hypotonia, dystonia or
ataxia), dysphagia, strabismus and seizures — as in LSFC.
Neuroimaging in two of our patients showed the appear-
ances of Leigh syndrome, as in LSFC, but the characteristic
brainstem lesions were absent in other patients. Moreover,
three of our patients had a striking leukoencephalopathy and
four patients showed cerebral malformations, which have
not been reported in LSFC (Table 1).
Episodes of severe, sometimes fatal, lactic acidosis are a
prominent feature of LSFC, seldom seen in patients with
other forms of Leigh syndrome (Debray et al., 2011;
Wedatilake et al., 2013). Similar episodes of lactic acidosis
occurred in many of our patients. The acidosis was often
accompanied by ketosis but there was no hyperglycaemia,
unlike the LSFC patients. Seven of our 10 patients had
episodes of severe lactic acidosis within a few days of
birth, often within the ﬁrst few hours. In contrast, only 6
of 36 patients with LSFC had neonatal episodes of severe
acidosis and the median age of presentation was 5 months
(Debray et al., 2011).
In LSFC, symptoms are limited to the brain and the epi-
sodes of acidosis, but a number of our patients had add-
itional problems. For example, two of our patients had
mild hypertrophic cardiomyopathy, a feature not previ-
ously observed in LSFC. More signiﬁcantly, four of our
patients had other congenital malformations, in addition
to the cerebral malformations mentioned previously. One
patient had complex congenital heart disease, another had
bilateral superior vena cava and a third had a bicuspid
aortic valve. Other malformations included hypospadias
(in two of the four reported males), an anteriorly placed
anus and polysyndactyly. Malformations have not been re-
ported in LSFC patients, though they often have distinctive
facial features, with a prominent forehead, broad nose and
mild hirsutism. Similar facial features were noted in a few
of our patients.
An intriguing aspect of our ﬁndings relates to the mito-
chondrial respiratory chain defects reported in patients with
LRPPRC mutation. Previously, biochemical investigation
of COX enzyme activity in patients with LSFC and a foun-
der LRPPRC mutation revealed normal Complex IV activ-
ity in kidney and heart, 50% of control activities in
ﬁbroblasts and skeletal muscle and a severe COX enzyme
defect in liver and brain (Merante et al., 1993; Sasarman
et al., 2010, 2015). Surprisingly, the residual Complex
IV activity in ﬁbroblasts was only decreased in three of
ﬁve patients we were able to test (Table 2) and did not
appear to correlate with the molecular abnormality. The
OXPHOS defect in LRPPRC patients is unlikely therefore
to be simply related to Complex IV deﬁciency, and muscle
samples from the homozygous p.(Arg1276_Lys1300del)
and the genetic compound p.[=,Glu497*];[Gly1050
Argfs*4] showing a combined Complex I and Complex
IV respiratory chain assembly defect (Fig. 5) further sup-
port these data. In addition, our observation is in agree-
ment with previous studies by Sasarman et al. (2015) that
demonstrated differences in OXPHOS activity and assem-
bly between distinct tissues in LSFC patients. Interestingly,
LRPPRC patient ﬁbroblasts harbouring the compound het-
erozygous p.[=,Glu497*];[Gly1050Argfs*4] mutation
showed a more striking defect in the assembly of all
OXPHOS complexes with the exception of Complex II.
Further differences were observed in the steady-state
levels of LRPPRC and OXPHOS subunits, which were
markedly decreased, compared to other patients. This
may reﬂect the more severe compound heterozygous frame-
shift and splice-defect nature of the mutations that make
the product vulnerable to nonsense-mediated mRNA decay
and subsequently affect the steady-state levels of LRPPRC
protein. Indeed, Sasarman et al. (2010) showed that the
steady-state levels of LRPPRC determine the extent of the
OXPHOS deﬁciency. The decrease in the steady-state
LRPPRC protein levels in the homozygous p.(Arg1276_
Lys1300del) patients is to a lesser extent compared to the
compound heterozygous LRPPRC patient. It is likely that
the predicted effect of the homozygous p.(Arg1276_
Lys1300del) in-frame deletion mutation may affect the
overall stability of the LRPPRC protein, which may explain
why the reduction in LRPPRC levels is not as severe for
Patients 1 and 2 compared to Patient 4.
Unexpectedly, biochemical studies suggest that homozy-
gous p.(Arg1276_Lys1300del) LRPPRC patient ﬁbroblasts
only show an isolated Complex IV deﬁciency, despite the
reduction in the steady-state levels of both Complex I and
Complex IV polypeptides. It has previously been suggested
that the instability of Complex I subunits may activate a
compensatory mechanism in the form of supercomplex for-
mation, thus allowing the formation of an active Complex I
(Calvaruso et al., 2012); it remains to be determined
whether supercomplex formation in the LRPPRC mutant
cells triggers such an adaptive response mechanism but is
an avenue for further research. Previous studies have also
shown that in Complex I-deﬁcient Ndufs4 knockout mice,
Complex III plays a major role in the stabilization of
Complex I (Calvaruso et al., 2012). Moreover, loss of the
Caenorhabditis elegans homologue of the mammalian
LRPPRC gene, mma-1, also showed a 50% reduction in
the levels of Complex I subunits while Complex I activity
remained unaffected (Rolland et al., 2013). Mitochondrial
hyperfusion appears to be responsible for the maintenance
of mitochondrial function in these animals. Interestingly,
the mitochondrial network in SH-SY5Y cells transfected
for 3 days with LRPPRC siRNA remains stable and hyper-
fused. However, after 5 days, mitochondrial fragmentation
occurs leading to a marked decrease in cellular ATP pro-
duction (Rolland et al., 2013). Fibroblasts from patients
with LSFC have also been shown to manifest fragmented
mitochondrial network (Sasarman et al., 2010;
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Burelle et al., 2015). It is, therefore, not unreasonable to
hypothesize that Complex IV deﬁciency triggers an initial
compensatory hyperfusion mechanism in LSFC patients’
ﬁbroblasts, which subsequently fails, leading to fragmented
mitochondrial network (Sasarman et al., 2010; Rolland
et al., 2013).
The precise molecular mechanism through which
LRPPRC stabilizes mitochondrial transcripts remains un-
clear. However, studies have shown that in order to stabil-
ize the majority of polyadenylated mitochondrial mRNAs,
LRPPRC forms a RNA-dependent protein complex with
SLIRP that protects the mRNAs from 3’ exoribonuclease
digestion (Sasarman et al., 2010, 2015; Chujo et al., 2012;
Ruzzenente et al., 2012). The reduction in LRPPRC steady-
state levels found in affected patients’ ﬁbroblasts and
muscle correlates with a decrease in SLIRP protein levels
(Fig. 6B) and these ﬁndings support the LRPPRC and
SLIRP interdependence in the regulation of mitochondrial
post-transcriptional mechanisms. Paradoxically, our data
suggest that despite the reduced stability of mitochondrial
MTND1 and RNA14 transcripts in homozygous
p.(Arg1276_Lys1300del) LRPPRC ﬁbroblasts, no obvious
changes in the translation of the encoded mitochondrial
polypeptides were found and the assembly of Complex I
and Complex V was normal. A global reduction in the
steady-state levels of mitochondrial mRNAs was also
found in LSFC ﬁbroblasts, yet the synthesis of some mito-
chondrial polypeptides was disproportionate, with the
exception of COX subunits (Sasarman et al., 2010). It
remains to be determined why the synthesis of some mito-
chondrial proteins is unaffected despite the global decrease
in steady-state levels of mitochondrial mRNAs in LRPPRC
patient cells. LRPPRC appears to be necessary for polyade-
nylation of mitochondrial mRNAs (Chujo et al., 2012;
Ruzzenente et al., 2012; Wilson et al., 2014), which can
modulate transcript stability (Wydro et al., 2010). To date
there are no studies describing the length of the poly(A) tail
of mitochondrial transcripts in LRPPRC patients. We show
that the poly(A) tail of the mitochondrial RNA14 mRNA
was unaffected in both homozygous and compound hetero-
zygous LRPPRC mutant individuals. Moreover, we did not
observe any signiﬁcant changes in the length of the poly(A)
tail of mitochondrial transcripts MTCO1, MTND3 or
RNA14 in cells depleted of LRPPRC or SLIRP
(Chrzanowska-Lightowlers, unpublished data). Further stu-
dies will be required to determine whether the polyadenyla-
tion status of different mitochondrial mRNAs in patients
carrying LRPPRC mutations is affected.
In conclusion, we have characterized the clinical and mo-
lecular nature of novel LRPPRC variants identiﬁed in
10 patients with early-onset COX deﬁciency associated
with multi-organ involvement. Molecular diagnosis of
mitochondrial disorders using next generation sequencing
has allowed us to identify new mutations within
LRPPRC gene outside of the French-Canadian population,
afﬁrming LRPPRC as a candidate gene in patients with
early-onset COX deﬁciency and neurological deﬁcits from
different ethnic backgrounds.
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